ELAVL4 and non-small cell lung carcinoma: Additionally, AAbs such as antinuclear, anti-thyroglobulin, anti-thyroid peroxidase, p53, BRCA2, HUD, and TRIM21 have been identified as predictors of PFS and overall survival (OS) in NSCLC undergoing ICIs therapy (20, 21, 22, 23).